Developing biomarker-specific end points in lung cancer clinical trials

Nature Reviews Clinical Oncology

Volumn 12, Issue 3, 2015, Pages 135-146

  Neal, Joel W ^a   Gainor, Justin F ^b   Shaw, Alice T ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; 3' FLUOROTHYMIDINE F 18; ALPHA FETOPROTEIN; ANAPLASTIC LYMPHOMA KINASE; B RAF KINASE; CA 125 ANTIGEN; CA 15-3 ANTIGEN; CA 19-9 ANTIGEN; CARBOPLATIN; CARCINOEMBRYONIC ANTIGEN; CELL FREE DNA; CHORIONIC GONADOTROPIN; CRIZOTINIB; CYCLIN D1; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITHELIAL CELL ADHESION MOLECULE; ERLOTINIB; FLUORODEOXYGLUCOSE F 18; GEFITINIB; KI 67 ANTIGEN; METHIONINE C 11; PACLITAXEL; PROGRAMMED DEATH 1 LIGAND 1; PROSTATE SPECIFIC ANTIGEN; SCATTER FACTOR RECEPTOR; THYROGLOBULIN; TUMOR MARKER; UNCLASSIFIED DRUG; UNINDEXED DRUG; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER;

ANTIGEN SPECIFICITY; APOPTOSIS; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CELLULAR IMMUNITY; CIRCULATING TUMOR CELL; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED TOMOGRAPHY; DNA SEQUENCE; DRUG DEVELOPMENT; DRUG EFFICACY; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN; LUNG CANCER; MOLECULAR IMAGING; NON SMALL CELL LUNG CANCER; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; QUALITY OF LIFE; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR VOLUME; VALIDATION PROCESS; BIOASSAY; GENETICS; LUNG NEOPLASMS; METABOLISM; MORTALITY; PROGNOSIS;

ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; ENDPOINT DETERMINATION; HUMANS; LUNG NEOPLASMS; PROGNOSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84923769218     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2014.222     Document Type: Review

References (127)

1. Goodman, L. S. et al. Nitrogen mustard therapy; use of methyl-bis (beta-chloroethyl) amine hydrochloride and tris (beta-chloroethyl) amine hydrochloride for hodgkin's disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders. J. Am. Med. Assoc. 132, 126-132 (1946
2. Farber, S.&Diamond, L. K. Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4 aminopteroyl glutamic acid. N. Engl. J. Med. 238, 787-793 (1948
3. National Comprehensive Cancer Network. NCCN guidelines for treatment of cancer by site: Non-Small Cell Lung Cancer [online], https://www.nccn.org/store/login/login.aspx?ReturnURL=http://www.nccn.org/professionals/physician-gls/pdf/nscl.pdf (2014
4. No authors listed] Chemotherapy in non-small cell lung cancer: a meta-Analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 311, 899-909 (1995
5. Scagliotti, G. V. et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non small cell lung cancer. J. Clin. Oncol. 26, 3543-3551 (2008
6. Hanna, N. et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non small cell lung cancer previously treated with chemotherapy. J. Clin. Oncol. 22, 1589-1597 (2004
7. Mok, T. S. et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361, 947-957 (2009
8. Shaw, A. T. et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N. Engl. J. Med. 368, 2385-2394 (2013
9. Sacher, A. G., Le, L. W.&Leighl, N. B. Shifting patterns in the interpretation of phase III clinical trial outcomes in advanced non small cell lung cancer: the bar is dropping. J. Clin. Oncol. 32, 1407-1411 (2014
10. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER). Guidance for Industry: Clinical Trial Endpoints for the Approval of Non-Small Cell Lung Cancer Drugs and Biologics; Draft Guidance [online], http://www.fda.gov/downloads/Drugs/Guidances/UCM259421.pdf (2011
11. Kwak, E. L. et al. Anaplastic lymphoma kinase inhibition in non small cell lung cancer. N. Engl. J. Med. 363, 1693-1703 (2010
12. Crinò, L. et al. Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005 [abstract]. J. Clin. Oncol. 29, a7514 (2011
13. Bunn, P. et al. Food and Drug Administration: Workshop Summary on Endpoints for Approval of Cancer Drugs for Lung Cancer [online], http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/CancerDrugs/ucm094744.pdf (2003
14. Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228-247 (2009
15. Miller, A. B., Hoogstraten, B., Staquet, M.&Winkler, A. Reporting results of cancer treatment. Cancer 47, 207-214 (1981
16. Oxnard, G. R. et al. Variability of lung tumor measurements on repeat computed tomography scans taken within 15 minutes. J. Clin. Oncol. 29, 3114-3119 (2011
17. Mozley, P. D. et al. Measurement of tumor volumes improves RECIST-based response assessments in advanced lung cancer. Transl. Oncol. 5, 19-25 (2012
18. Nishino, M. et al. CT tumor volume measurement in advanced non small cell lung cancer: performance characteristics of an emerging clinical tool. Acad. Radiol. 18, 54-62 (2011
19. Wolchok, J. D. et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res. 15, 7412-7420 (2009
20. Kircher, M. F., Hricak, H.&Larson, S. M. Molecular imaging for personalized cancer care. Mol. Oncol. 6, 182-195 (2012
21. Cheson, B. D. Role of functional imaging in the management of lymphoma. J. Clin. Oncol. 29, 1844-1854 (2011
22. Prior, J. O. et al. Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor. J. Clin. Oncol. 27, 439-445 (2009
23. Weber, W. A. et al. Positron emission tomography in non small cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J. Clin. Oncol. 21, 2651-2657 (2003
24. Mac Manus, M. P. et al. Positron emission tomography is superior to computed tomography scanning for response-Assessment after radical radiotherapy or chemoradiotherapy in patients with non small cell lung cancer. J. Clin. Oncol. 21, 1285-1292 (2003).
25. Machtay, M. et al. Prediction of survival by [18F]fluorodeoxyglucose positron emission tomography in patients with locally advanced non small cell lung cancer undergoing definitive chemoradiation therapy: results of the ACRIN 6668/RTOG 0235 trial. J. Clin. Oncol. 31, 3823-3830 (2013
26. Cuaron, J., Dunphy, M.&Rimner, A. Role of FDG-PET scans in staging, response assessment, and follow-up care for non-small cell lung cancer. Front. Oncol. 2, 208 (2012
27. Rasey, J. S., Grierson, J. R., Wiens, L. W., Kolb, P. D.&Schwartz, J. L. Validation of FLT uptake as a measure of thymidine kinase 1 activity in A549 carcinoma cells. J. Nucl. Med. 43, 1210-1217 (2002
28. Buck, A. K. et al. 3 deoxy 3-[18F]fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules. Cancer Res. 62, 3331-3334 (2002
29. Yang, W. et al. Imaging of proliferation with 18F FLT PET/CT versus 18F-FDG PET/CT in non small cell lung cancer. Eur. J. Nucl. Med. Mol. Imaging 37, 1291-1299 (2010
30. Sohn, H. J. et al. [18F]Fluorothymidine positron emission tomography before and 7 days after gefitinib treatment predicts response in patients with advanced adenocarcinoma of the lung. Clin. Cancer Res. 14, 7423-7429 (2008
31. Leonard, J. P. et al. Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood 119, 4597-4607 (2012
32. Holland, J. P., Cumming, P.&Vasdev, N. PET of signal transduction pathways in cancer. J. Nucl. Med. 53, 1333-1336 (2012
33. Mankoff, D. A., Pryma, D. A.&Clark, A. S. Molecular imaging biomarkers for oncology clinical trials. J. Nucl. Med. 55, 525-528 (2014
34. Weber, B. et al. Erlotinib accumulation in brain metastases from non-small cell lung cancer: visualization by positron emission tomography in a patient harboring a mutation in the epidermal growth factor receptor. J. Thorac. Oncol. 6, 1287-1289 (2011
35. Memon, A. A. et al. PET imaging of patients with non-small cell lung cancer employing an EGF receptor targeting drug as tracer. Br. J. Cancer 105, 1850-1855 (2011
36. Bahce, I. et al. Development of [11C]erlotinib positron emission tomography for in vivo evaluation of EGF receptor mutational status. Clin. Cancer Res. 19, 183-193 (2013
37. Scher, H. I. et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 375, 1437-1446 (2010
38. Topalian, S. L. et al. Safety, activity, and immune correlates of anti PD 1 antibody in cancer. N. Engl. J. Med. 366, 2443-2454 (2012
39. Brahmer, J. R. et al. Safety and activity of anti PD L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455-2465 (2012
40. Hamid, O. et al. Safety and tumor responses with lambrolizumab (anti PD 1) in melanoma. N. Engl. J. Med. 369, 134-144 (2013
41. US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research. Guidance for Industry: Clinical Considerations for Therapeutic Cancer Vaccines [online], http://www.fda.gov/downloads/biologicsbloodvaccines/guidancecomplianceregulatoryinformation/guidances/vaccines/ucm278673.pdf (2011
42. Aarntzen, E. H. et al. In vivo imaging of therapy-induced anti-cancer immune responses in humans. Cell. Mol. Life Sci. 70, 2237-2257 (2013
43. Rustin, G. J. et al. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int. J. Gynecol. Cancer 21, 419-423 (2011
44. Scher, H. I. et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J. Clin. Oncol. 26, 1148-1159 (2008).
45. Yoshimasu, T. et al. Disappearance curves for tumor markers after resection of intrathoracic malignancies. Int. J. Biol. Markers 14, 99-105 (1999
46. Riedinger, J. M. et al. CA 125 half-life and CA 125 nadir during induction chemotherapy are independent predictors of epithelial ovarian cancer outcome: results of a French multicentric study. Ann. Oncol. 17, 1234-1238 (2006
47. Krebs, M. G. et al. Molecular analysis of circulating tumour cells-biology and biomarkers. Nat. Rev. Clin. Oncol. 11, 129-144 (2014
48. Janssen Diagnostics. CELLSEARCH® Circulating Tumor Cell Test [online], https://www.cellsearchctc.com (2014
49. Hayes, D. F. et al. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin. Cancer Res. 12, 4218-4224 (2006
50. Krebs, M. G. et al. Evaluation and prognostic significance of circulating tumor cells in patients with non small cell lung cancer. J. Clin. Oncol. 29, 1556-1563 (2011
51. Maheswaran, S. et al. Detection of mutations in EGFR in circulating lung-cancer cells. N. Engl. J. Med. 359, 366-377 (2008
52. Pailler, E. et al. Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non small cell lung cancer. J. Clin. Oncol. 31, 2273-2281 (2013
53. Punnoose, E. A. et al. Evaluation of circulating tumor cells and circulating tumor DNA in non small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib. Clin. Cancer Res. 18, 2391-2401 (2012).
54. Diehl, F. et al. Circulating mutant DNA to assess tumor dynamics. Nat. Med. 14, 985-990 (2008
55. Sozzi, G. et al. Quantification of free circulating DNA as a diagnostic marker in lung cancer. J. Clin. Oncol. 21, 3902-3908 (2003
56. Gautschi, O. et al. Circulating deoxyribonucleic acid as prognostic marker in non small cell lung cancer patients undergoing chemotherapy. J. Clin. Oncol. 22, 4157-4164 (2004
57. Kimura, H. et al. Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non small cell lung cancer. Clin. Cancer Res. 12, 3915-3921 (2006
58. Kuang, Y. et al. Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer. Clin. Cancer Res. 15, 2630-2636 (2009
59. Rosell, R. et al. Screening for epidermal growth factor receptor mutations in lung cancer. N. Engl. J. Med. 361, 958-967 (2009
60. Taniguchi, K. et al. Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas. Clin. Cancer Res. 17, 7808-7815 (2011
61. Oxnard, G. R. et al. Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin. Cancer Res. 20, 1698-1705 (2014
62. Murtaza, M. et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 497, 108-112 (2013
63. Newman, A. M. et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat. Med. 20, 548-554 (2014
64. Dawson, S. J., Rosenfeld, N.&Caldas, C. Circulating tumor DNA to monitor metastatic breast cancer. N. Engl. J. Med. 369, 93-94 (2013
65. Wang, W. et al. Biomarkers on melanoma patient T cells associated with ipilimumab treatment. J. Transl. Med. 10, 146 (2012
66. Comin-Anduix, B. et al. Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-Associated antigen 4 blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma. J. Transl. Med. 6, 22 (2008
67. Grosso, J. F.&Jure-Kunkel, M. N. CTLA 4 blockade in tumor models: an overview of preclinical and translational research. Cancer Immun. 13, 5 (2013
68. Morse, M. A., Osada, T., Hobeika, A., Patel, S.&Lyerly, H. K. Biomarkers and correlative endpoints for immunotherapy trials. Am. Soc. Clin. Oncol. Educ. Book http://dx.doi.org/10.1200/EdBook-AM.2013.33.e287 (2013
69. Rojo, F., Dalmases, A., Corominas, J. M.&Albanell, J. Pharmacodynamics: biological activity of targeted therapies in clinical trials. Clin. Transl. Oncol. 9, 634-644 (2007
70. Ang, J. E., Kaye, S.&Banerji, U. Tissue-based approaches to study pharmacodynamic endpoints in early phase oncology clinical trials. Curr. Drug Targets 13, 1525-1534 (2012
71. Adjei, A. A. et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small molecule mitogen-Activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY 142886) in patients with advanced cancers. J. Clin. Oncol. 26, 2139-2146 (2008
72. Yap, T. A. et al. Phase I trial of a selective c MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies. J. Clin. Oncol. 29, 1271-1279 (2011
73. Trunzer, K. et al. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J. Clin. Oncol. 31, 1767-1774 (2013
74. Felip, E. et al. A phase II pharmacodynamic study of erlotinib in patients with advanced non-small cell lung cancer previously treated with platinum based chemotherapy. Clin. Cancer Res. 14, 3867-3874 (2008
75. Spector, N. L. et al. Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J. Clin. Oncol. 23, 2502-2512 (2005
76. Flaherty, K. T. et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809-819 (2010
77. Shapiro, G. I. et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors. Clin. Cancer Res. 20, 233-245 (2014
78. Armstrong, A. J. et al. A pharmacodynamic study of rapamycin in men with intermediate-To high-risk localized prostate cancer. Clin. Cancer Res. 16, 3057-3066 (2010
79. Weekes, C. D. et al. Multicenter phase I trial of the mitogen-Activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer. Clin. Cancer Res. 19, 1232-1243 (2013
80. Banerji, U. et al. Phase I pharmacokinetic and pharmacodynamic study of 17-Allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J. Clin. Oncol. 23, 4152-4161 (2005
81. Bundred, N. et al. Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a phase I multicentre trial in patients scheduled for elective breast cancer surgery. Invest. New Drugs 31, 949-958 (2013
82. Venugopal, B. et al. A phase I study of quisinostat (JNJ 26481585), an oral hydroxamate histone deacetylase inhibitor with evidence of target modulation and antitumor activity, in patients with advanced solid tumors. Clin. Cancer Res. 19, 4262-4272 (2013
83. Gomez-Roca, C. A. et al. Sequential research-related biopsies in phase I trials: acceptance, feasibility and safety. Ann. Oncol. 23, 1301-1306 (2012
84. Dowlati, A. et al. Sequential tumor biopsies in early phase clinical trials of anticancer agents for pharmacodynamic evaluation. Clin. Cancer Res. 7, 2971-2976 (2001
85. Tam, A. L. et al. Feasibility of image-guided transthoracic core-needle biopsy in the BATTLE lung trial. J. Thorac. Oncol. 8, 436-442 (2013
86. Sequist, L. V. et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci. Transl. Med. 3, 75ra26 (2011
87. Arcila, M. E. et al. Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid based assay. Clin. Cancer Res. 17, 1169-1180 (2011
88. Katayama, R. et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci. Transl. Med. 4, 120ra117 (2012
89. Doebele, R. C. et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin. Cancer Res. 18, 1472-1482 (2012
90. Awad, M. M. et al. Acquired resistance to crizotinib from a mutation in CD74-ROS1. N. Engl. J. Med. 368, 2395-2401 (2013
91. Gainor, J. F.&Shaw, A. T. Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer. J. Clin. Oncol. 31, 3987-3996 (2013
92. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01074177?term=NCT01074177&rank=1 (2014
93. Kobayashi, S. et al. EGFR mutation and resistance of non small cell lung cancer to gefitinib. N. Engl. J. Med. 352, 786-792 (2005
94. Lai, T. L., Lavori, P. W.&Shih, M. C. Sequential design of phase II-III cancer trials. Stat. Med. 31, 1944-1960 (2012
95. Wozniak, A. J. et al. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non small cell lung cancer: a Southwest Oncology Group study. J. Clin. Oncol. 16, 2459-2465 (1998
96. Sandler, A. B. et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non small cell lung cancer. J. Clin. Oncol. 18, 122-130 (2000
97. Shepherd, F. A. et al. Erlotinib in previously treated non small cell lung cancer. N. Engl. J. Med. 353, 123-132 (2005
98. Shepherd, F. A. et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non small cell lung cancer previously treated with platinum-based chemotherapy. J. Clin. Oncol. 18, 2095-2103 (2000
99. Sandler, A. et al. Paclitaxel-carboplatin alone or with bevacizumab for non small cell lung cancer. N. Engl. J. Med. 355, 2542-2550 (2006
100. Rosell, R. et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non small cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 13, 239-246 (2012
101. Sequist, L. V. et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J. Clin. Oncol. 31, 3327-3334 (2013
102. Sequist, L. V. et al. First in human evaluation of CO 1686, an irreversible, highly selective tyrosine kinase inhibitor of mutations of EGFR (activating and T790M) [abstract]. J. Clin. Oncol. 32 (Suppl. 5s), a8010 (2014
103. Janne, P. A. et al. Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients (pts) with EGFR inhibitor-resistant non-small cell lung cancer (NSCLC) [abstract]. J. Clin. Oncol. 32 (Suppl. 5s), a8009 (2014
104. Camidge, D. R. et al. Activity and safety of crizotinib in patients with ALK-positive non small cell lung cancer: updated results from a phase 1 study. Lancet Oncol. 13, 1011-1019 (2012
105. Shaw, A. T. et al. Ceritinib in ALK-rearranged non small cell lung cancer. N. Engl. J. Med. 370, 1189-1197 (2014
106. Gadgeel, S. M. et al. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non small cell lung cancer (AF 002JG): results from the dose-finding portion of a phase 1/2 study. Lancet Oncol. 15, 1119-1128 (2014
107. Planchard, D. et al. Interim results of phase II study BRF113928 of dabrafenib in BRAF V600E mutation-positive non-small cell lung cancer (NSCLC) patients [abstract]. J. Clin. Oncol. 31, a8009 (2013
108. Kramer, G. M. et al. CT perfusion versus [15O]H2O PET in lung tumors: effects of CT perfusion methodology. Med. Phys. 40, 052502 (2013
109. Bruehlmeier, M., Roelcke, U., Schubiger, P. A.&Ametamey, S. M. Assessment of hypoxia and perfusion in human brain tumors using PET with 18F-fluoromisonidazole and 15O H2O. J. Nucl. Med. 45, 1851-1859 (2004
110. Eschmann, S. M. et al. Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J. Nucl. Med. 46, 253-260 (2005
111. Dehdashti, F. et al. In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM. Eur. J. Nucl. Med. Mol. Imaging 30, 844-850 (2003
112. Dehdashti, F. et al. Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu ATSM: relationship to therapeutic response-A preliminary report. Int. J. Radiat. Oncol. Biol. Phys. 55, 1233-1238 (2003
113. Dietz, D. W. et al. Tumor hypoxia detected by positron emission tomography with 60Cu-ATSM as a predictor of response and survival in patients undergoing neoadjuvant chemoradiotherapy for rectal carcinoma: a pilot study. Dis. Colon Rectum 51, 1641-1648 (2008
114. Terakawa, Y. et al. Diagnostic accuracy of 11C-methionine PET for differentiation of recurrent brain tumors from radiation necrosis after radiotherapy. J. Nucl. Med. 49, 694-699 (2008
115. Aki, T. et al. Evaluation of brain tumors using dynamic 11C methionine PET. J. Neurooncol. 109, 115-122 (2012
116. Pruim, J. et al. Brain tumors: L [1 C 11]tyrosine PET for visualization and quantification of protein synthesis rate. Radiology 197, 221-226 (1995
117. de Boer, J. R. et al. L 1 11C-Tyrosine PET in patients with laryngeal carcinomas: comparison of standardized uptake value and protein synthesis rate. J. Nucl. Med. 44, 341-346 (2003
118. Nguyen, Q. D., Challapalli, A., Smith, G., Fortt, R.&Aboagye, E. O. Imaging apoptosis with positron emission tomography: bench to bedside development of the caspase 3/7 specific radiotracer [18F]ICMT 11. Eur. J. Cancer 48, 432-440 (2012
119. Challapalli, A. et al. 18F ICMT 11, a caspase 3 specific PET tracer for apoptosis: biodistribution and radiation dosimetry. J. Nucl. Med. 54, 1551-1556 (2013
120. Yagle, K. J. et al. Evaluation of 18F-Annexin V as a PET imaging agent in an animal model of apoptosis. J. Nucl. Med. 46, 658-666 (2005
121. Dumont, R. A. et al. Novel 64Cu-And 68Ga-labeled RGD conjugates show improved PET imaging of a?β3 integrin expression and facile radiosynthesis. J. Nucl. Med. 52, 1276-1284 (2011
122. Beer, A. J.&Schwaiger, M. Imaging of integrin alphavbeta3 expression. Cancer Metastasis Rev. 27, 631-644 (2008
123. Wang, H. et al. A new PET tracer specific for vascular endothelial growth factor receptor 2. Eur. J. Nucl. Med. Mol. Imaging 34, 2001-2010 (2007
124. Umbehr, M. H., Müntener, M., Hany, T., Sulser, T.&Bachmann, L. M. The role of 11C-choline and 18F fluorocholine positron emission tomography (PET) and PET/CT in prostate cancer: a systematic review and meta-Analysis. Eur. Urol. 64, 106-117 (2013
125. Poeppel, T. D. et al. 68Ga-DOTATOC versus 68Ga DOTATATE PET/CT in functional imaging of neuroendocrine tumors. J. Nucl. Med. 52, 1864-1870 (2011
126. Linden, H. M. et al. Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. J. Clin. Oncol. 24, 2793-2799 (2006
127. Dijkers, E. C. et al. Biodistribution of 89Zr trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin. Pharmacol. Ther. 87, 586-592 (2010